dosage of dalteparin sodium injection

2022-03-10 14:31:17

note: the same drug may have different usages or dosages due to different packaging specifications. this article is for reference only. if you are unsure, refer to the instructions that came with your medication or ask your doctor.

If necessary, anti-Xa can be measured to monitor the activity of dalteparin sodium.

1 Treatment of acute deep vein thrombosis. Daparin sodium can be injected subcutaneously once daily or twice daily. Once daily usage: 200 IU/kg body weight, subcutaneous injection once daily, anticoagulant effect does not need to be monitored. The total daily amount cannot be raised by more than 18000 IU. Twice daily usage: 100 IU/kg body weight, subcutaneously twice daily, this dose is indicated for patients with a high risk of bleeding. Usually no monitoring is required during treatment, but functional anti--Xa assays can be performed. 3-4 hours after subcutaneous injection, the maximum blood concentration can be measured. The recommended blood concentration ranges from 0.5-1.0IU anti-Xa/ml. At the same time as sodium daparin, the vitamin K antagonist can be taken orally immediately. Treatment with daparin sodium should be continued until the level of the prothrombin complex (factor I.VII.IX.X) drops to therapeutic levels. Combination therapy usually takes at least 5 days. Prevention of clotting during hemodialysis and blood filtration.

2 Chronic renal failure, patients have no known risk of bleeding: hemodialysis and blood filtration for no more than 4 hours: the dose is as follows or intravenous Rapid injection of 5000 IU. Hemodialysis and blood filtration for more than 4 hours: rapid intravenous injection of 30-40 IU/ kg body weight, followed by intravenous infusion of 10-15 IU / kg body weight per hour. Under normal circumstances, when patients apply this product for long-term hemodialysis, the number of dose adjustments is very small, so the number of anti-Xa concentrations is also very small. The dose administered usually keeps the plasma concentration in the range of 0.5-1.0 IU anti-Xa / ml.

3 Patients with acute renal failure, patients with a high risk of bleeding: rapid intravenous injection of 5-10 IU/kg body weight, followed by intravenous infusion of 4-5 IU/kg body weight per hour for acute hemodialysis patients with shorter intervals of treatment, should be adversarial - Xa for comprehensive monitoring. Plasma concentrations should be maintained in the range of 0.2-0.4 IU anti-Xa/ml.

4 Unstable coronary artery disease, such as unstable angina and non-Q-wave myocardial infarction. Subcutaneously 120 IU/kg twice daily. The maximum dose is 10000 IU / 12 hours. Treatment is given for at least 6 days, which can be extended if the doctor deems necessary. Concomitant use of low-dose acetylsalicylic acid is recommended.

5 Prevention of surgery-related thrombosis:

(1) Major surgery with risk of thromboembolic complications: subcutaneous injection of 2500 IU 1-2 hours before surgery, subcutaneous injection of 2500 IU every morning after surgery until the patient is active, generally taking 5-7 days or more.

(2) Major surgery and orthopedic surgery with other risk factors: 5000 IU is injected subcutaneously at night before surgery, and 5000 IU is injected subcutaneously every night after surgery. Treatment should be continued until the patient is mobile, usually for 5 to 7 days or more. In addition, it is also possible to inject 2500 IU subcutaneously 1-2 hours before surgery and 2500 IU subcutaneously 8-12 hours after surgery. Then every morning subcutaneously 5000 IU is injected.